LPL Financial LLC Raises Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

LPL Financial LLC lifted its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 67.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 257,449 shares of the company's stock after buying an additional 103,495 shares during the quarter. LPL Financial LLC's holdings in ImmunityBio were worth $659,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Swiss National Bank increased its position in ImmunityBio by 1.5% during the fourth quarter. Swiss National Bank now owns 274,000 shares of the company's stock worth $701,000 after acquiring an additional 4,000 shares during the period. Teacher Retirement System of Texas increased its position in ImmunityBio by 20.4% during the fourth quarter. Teacher Retirement System of Texas now owns 41,742 shares of the company's stock worth $107,000 after acquiring an additional 7,067 shares during the period. Commonwealth Equity Services LLC increased its position in ImmunityBio by 40.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,955 shares of the company's stock worth $74,000 after acquiring an additional 8,380 shares during the period. E Fund Management Co. Ltd. increased its position in ImmunityBio by 32.9% during the fourth quarter. E Fund Management Co. Ltd. now owns 38,900 shares of the company's stock worth $100,000 after acquiring an additional 9,622 shares during the period. Finally, Copperwynd Financial LLC increased its position in ImmunityBio by 99.1% during the fourth quarter. Copperwynd Financial LLC now owns 20,087 shares of the company's stock worth $51,000 after acquiring an additional 10,000 shares during the period. Institutional investors and hedge funds own 8.58% of the company's stock.

ImmunityBio Trading Down 5.3 %

NASDAQ IBRX traded down $0.14 during trading hours on Tuesday, hitting $2.49. The company's stock had a trading volume of 4,426,648 shares, compared to its average volume of 5,282,061. ImmunityBio, Inc. has a 52 week low of $2.28 and a 52 week high of $10.01. The company's 50-day simple moving average is $2.82 and its two-hundred day simple moving average is $3.46. The company has a market capitalization of $2.13 billion, a PE ratio of -2.71 and a beta of 0.51.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.11. The business had revenue of $7.55 million during the quarter, compared to analysts' expectations of $8.74 million. Research analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on IBRX. HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of ImmunityBio in a report on Monday. BTIG Research began coverage on shares of ImmunityBio in a report on Friday, January 10th. They issued a "buy" rating and a $6.00 target price on the stock. Finally, D. Boral Capital reissued a "buy" rating and issued a $30.00 target price on shares of ImmunityBio in a report on Wednesday, April 23rd. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $12.19.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.